全文获取类型
收费全文 | 6821篇 |
免费 | 1810篇 |
国内免费 | 94篇 |
学科分类
医药卫生 | 8725篇 |
出版年
2024年 | 1篇 |
2023年 | 62篇 |
2022年 | 61篇 |
2021年 | 159篇 |
2020年 | 361篇 |
2019年 | 542篇 |
2018年 | 596篇 |
2017年 | 559篇 |
2016年 | 598篇 |
2015年 | 522篇 |
2014年 | 593篇 |
2013年 | 532篇 |
2012年 | 505篇 |
2011年 | 479篇 |
2010年 | 437篇 |
2009年 | 278篇 |
2008年 | 284篇 |
2007年 | 222篇 |
2006年 | 209篇 |
2005年 | 202篇 |
2004年 | 192篇 |
2003年 | 328篇 |
2002年 | 287篇 |
2001年 | 224篇 |
2000年 | 187篇 |
1999年 | 100篇 |
1998年 | 48篇 |
1997年 | 54篇 |
1996年 | 18篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 5篇 |
1992年 | 11篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 5篇 |
1985年 | 11篇 |
1984年 | 8篇 |
1983年 | 11篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有8725条查询结果,搜索用时 14 毫秒
1.
《The Journal of thoracic and cardiovascular surgery》2023,165(1):327-334.e2
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone. 相似文献
2.
3.
《Journal of vascular and interventional radiology : JVIR》2022,33(8):964-971.e2
PurposeTo assess the cost effectiveness of microwave ablation (MWA) and stereotactic body radiotherapy (SBRT) for patients with inoperable stage I non–small cell lung cancer (NSCLC).Materials and MethodsA literature search was performed in MEDLINE with broad search clusters. A decision-analytic model was constructed over a 5-year period. The model incorporated treatment-related complications and long-term recurrence. All clinical parameters were derived from the literature with preference to long-term prospective trials. A healthcare payers’ perspective was adopted. Outcomes were measured in quality-adjusted life years (QALYs) extracted from prior studies and U.S. dollars from Medicare reimbursements and prior studies. Base case calculations, probabilistic sensitivity analysis with 10,000 Monte Carlo simulations, and multiple 1- and 2-way sensitivity analyses were performed.ResultsMWA yielded a health benefit of 2.31 QALYs at a cost of $195,331, whereas SBRT yielded a health benefit of 2.33 QALYs at a cost of $225,271. The incremental cost-effectiveness ratio was $1,480,597/QALY, indicating that MWA is the more cost-effective strategy. The conclusion remains unchanged in probabilistic sensitivity analysis with MWA being the optimal cost strategy in 99.84% simulations. One-way sensitivity analyses revealed that MWA remains cost effective when its annual recurrence risk is <18.4% averaged over 5 years, when the SBRT annual recurrence risk is >1.44% averaged over 5 years, or when MWA is at least $7,500 cheaper than SBRT.ConclusionsMWA appears to be more cost effective than SBRT for patients with inoperable stage I NSCLC. 相似文献
4.
1文献来源Jabbour SK,Lee KH,Frost N,et al.Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable,locally advanced,stageⅢnon?small cell lung cancer.The phase 2 KEYNOTE?799 nonrandomized trial[J].JAMA Oncol,2021,7(9):1-9. 相似文献
5.
6.
7.
8.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2022,34(11):698-700
A patient view paper focused on hopes and challenges facing the never smoker lung cancer population – from lived experience, unexpected diagnosis, treatment and subsequent immersion in lung cancer research and patient advocacy over many years, citing examples, references and events organised to explore the subject by UK research institutions.Material/methodsBased on lived experience, invited patient perspective conference presentations including National Cancer Research Institute (NCRI) never smoker lung cancer research strategy event opening presentation and subsequent article, includes references to relevant papers/findings and points raised during research events/group discussions, alongside personal experiences and beliefs.ResultsDiscussions with clinicians, events, surveys, meetings and virtual discussions all revealed a dearth of evidence available to identify the best way to deal with this patient cohort at almost every aspect of their experience – from missed/late diagnosis, to screening potential (non-existent), mutation driven treatments (what about those ineligible?), and psychosocial/psychological aspects given their different life stage from older traditional lung cancer patients.ConclusionMore effort and focus are needed to better understand what is driving these cases, how best to detect them sooner and respond/refer to treatments as well as developing screening methods alongside increased public and healthcare professional awareness raising and tools to support clinicians in earlier detection. 相似文献
9.